ORIGINAL ARTICLE

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study

V G Athyros¹, D P Mikhailidis³, A A Papageorgiou², A N Symeonidis⁴, A N Pehlivanidis¹, V I Bouloukos¹, M Elisaf⁵

¹ Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece
² Second Propedeutic Department of Internal Medicine, Aristotelian University
³ Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, London NW3 2QG, UK
⁴ Greek Society of General Practitioners, 21 N. Koudourioti St, Thessaloniki, 546 25, Greece
⁵ Department of Internal Medicine, Medical School, University of Ioannina, 451 10, Greece

Correspondence to:
Correspondence to:
Dr V G Athyros
15 Marmara St, Thessaloniki, 551 32, Greece; athyros{at}med.auth.gr

Background: Little is known about statins in the prevention of dyslipidaemia induced renal function decline. The secondary coronary heart disease (CHD) prevention GREACE study suggested that dose titration with atorvastatin (10–80 mg/day, mean dose 24 mg/day) achieves the national cholesterol educational programme treatment goals and significantly reduces morbidity and mortality, compared with usual care.

Aims: To report the effect of statin on renal function compared with untreated dyslipidaemia in both treatment groups.

Methods/Results: All patients had plasma creatinine values within the reference range < 115 µmol/litre (13 mg/litre). The on study creatinine clearance (CrCl), as estimated (for up to 48 months) by the Cockroft-Gault formula, was compared within and between treatment groups using analysis of variance to assess differences over time. Patients from both groups not treated with statins (704) showed a 5.2% decrease in CrCl (p < 0.0001). Usual care patients on various statins (97) had a 4.9% increase in CrCl (p = 0.003). Structured care patients on atorvastatin (783) had a 12% increase in CrCl (p < 0.0001). This effect was more prominent in the lower two quartiles of baseline CrCl and with higher atorvastatin doses. After adjustment for 25 predictors of all CHD related events, multivariate analysis revealed a hazards ratio of 0.84 (confidence interval 0.73 to 0.95; p = 0.003) with every 5% increase in CrCl.

Conclusions: In untreated dyslipidaemic patients with CHD and normal renal function at baseline, CrCl declines over a period of three years. Statin treatment prevents this decline and significantly improves renal function, potentially offsetting an additional factor associated with CHD risk.

Abbreviations: ACE, angiotensin converting enzyme; C, cholesterol; CHD, coronary heart disease; CI, confidence interval; CrCl, creatinine clearance; GFR, glomerular filtration rate; GREACE, Greek atorvastatin and coronary heart disease evaluation; HDL, high density lipoprotein; HPS, heart protection study; HR, hazard ratio; K/DOQI, kidney disease outcomes and quality initiative; LDL, low density lipoprotein; NCEP, national cholesterol educational programme; SCr, serum creatinine; TG, triglyceride

Keywords: renal function; dyslipidaemia; statins; coronary heart disease

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Cormack-Aboud, F. C., Brinkkoetter, P. T., Pippin, J. W., Shankland, S. J., Durvasula, R. V. (2009). Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 24: 404-412 [Abstract] [Full Text]  
• Pagourelias, E. D., Koumaras, C., Kakafika, A. I., Tziomalos, K., Zorou, P. G., Athyros, V. G., Karagiannis, A. (2009). Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?. ANGIOLOGY 60: 74-81 [Abstract]  
• Athyros, V. G., Kakafika, A. I., Tziomalos, K., Karagiannis, A., Mikhailidis, D. P. (2008). CORONA, Statins, and Heart Failure: Who Lost the Crown?. ANGIOLOGY 59: 5-8  
• Levine, A. P., Mikhailidis, D. P., Moross, T., Benson, K., Gor, M. (2008). Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. ANGIOLOGY 59: 36-46 [Abstract]  
• RIFKIN, D., SARNAK, M. (2008). Q: Should all patients with chronic kidney disease take a statin?. Cleveland Clinic Journal of Medicine 75: 118-120 [Full Text]  
• Kostapanos, M. S., Milionis, H. J., Saougos, V. G., Lagos, K. G., Kostara, C., Bairaktari, E. T., Elisaf, M. S. (2007). Dose-Dependent Effect of Rosuvastatin Treatment on Urinary Protein Excretion. J CARDIOVASC PHARMACOL THER 12: 292-297 [Abstract]  
• Campese, V. M., Park, J. (2007). HMG-CoA Reductase Inhibitors and Renal Function. CJASN 2: 1100-1103 [Full Text]  
• Shepherd, J., Kastelein, J. J.P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., Wenger, N. K., for the Treating to New Targets Investigators, (2007). Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study. CJASN 2: 1131-1139 [Abstract] [Full Text]  
• Agarwal, R. (2007). Effects of Statins on Renal Function. Mayo Clin Proc. 82: 1381-1390 [Abstract] [Full Text]  
• Romayne Kurukulasuriya, L., Athappan, G., Saab, G., Whaley Connell, A., Sowers, J. R. (2007). Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Ther Adv Cardiovasc Dis 1: 49-59 [Abstract]  
• Korantzopoulos, P., Elisaf, M., Milionis, H. J. (2007). Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease ready for prime time?. Nephrol Dial Transplant 22: 2768-2774 [Full Text]  
• Nanayakkara, P. W. B., van Guldener, C., ter Wee, P. M., Scheffer, P. G., van Ittersum, F. J., Twisk, J. W., Teerlink, T., van Dorp, W., Stehouwer, C. D. A. (2007). Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease: Results From the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167: 1262-1270 [Abstract] [Full Text]  
• Athyros, V. G., Karagiannis, A., Kakafika, A., Elisaf, M., Mikhailidis, Dimitri. P. (2007). Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant 22: 963-964 [Full Text]  
• Athyros, V. G., Mikhailidis, D. P., Liberopoulos, E. N., Kakafika, A. I., Karagiannis, A., Papageorgiou, A. A., Tziomalos, K., Ganotakis, E. S., Elisaf, M. (2007). Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 22: 118-127 [Abstract] [Full Text]  
• Save, V., Patil, N., Moulik, N., Rajadhyaksha, G. (2006). Effect of Atorvastatin on Type 2 Diabetic Dyslipidemia. J CARDIOVASC PHARMACOL THER 11: 262-270 [Abstract]  
• Atthobari, J., Brantsma, A. H., Gansevoort, R. T., Visser, S. T., Asselbergs, F. W., van Gilst, W. H., de Jong, P. E., de Jong-van den Berg, L. T. W., on behalf of PREVEND study group, (2006). The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 21: 3106-3114 [Abstract] [Full Text]  
• Kostapanos, M. S., Milionis, H. J., Gazi, I., Kostara, C., Bairaktari, E. T., Elisaf, M. (2006). Rosuvastatin Increases {alpha}-1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia.. J Clin Pharmacol 46: 1337-1343 [Abstract] [Full Text]  
• Molitch, M. E. (2006). Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease. CJASN 1: 1090-1099 [Abstract] [Full Text]  
• Sandhu, S., Wiebe, N., Fried, L. F., Tonelli, M. (2006). Statins for Improving Renal Outcomes: A Meta-Analysis. J. Am. Soc. Nephrol. 17: 2006-2016 [Abstract] [Full Text]  
• Tovar, J. M., Schering, D. B. (2006). Management of Dyslipidemia in Special Populations. Journal of Pharmacy Practice 19: 63-78 [Abstract]  
• Segura, J., Garcia-Donaire, J. A., Praga, M., Ruilope, L. M. (2006). Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients. J. Am. Soc. Nephrol. 17: S136-S140 [Abstract] [Full Text]  
• D'Amico, G. (2006). Statins and Renal Diseases: From Primary Prevention to Renal Replacement Therapy.. J. Am. Soc. Nephrol. 17: S148-S152 [Abstract] [Full Text]  
• Alnaeb, M. E., Youssef, F., Mikhailidis, D. P., Hamilton, G. (2006). Short-term Lipid-Lowering Treatment with Atorvastatin Improves Renal Function But Not Renal Blood Flow Indices in Patients with Peripheral Arterial Disease. ANGIOLOGY 57: 65-71 [Abstract]  
• Panchapakesan, U., Sumual, S., Pollock, C. A., Chen, X. (2005). PPAR{gamma} agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am. J. Physiol. Renal Physiol. 289: F1153-F1158 [Abstract] [Full Text]  
• Paraskevas, K. I., Daskalopoulou, S. S., Daskalopoulos, M. E., Liapis, C. D. (2005). Secondary Prevention of Ischemic Cerebrovascular Disease. What Is the Evidence?. ANGIOLOGY 56: 539-552 [Abstract]  
• Milionis, H. J., Gazi, I. F., Filippatos, T. D., Tzovaras, V., Chasiotis, G., Goudevenos, J., Seferiadis, K., Elisaf, M. S. (2005). Starting with Rosuvastatin in Primary Hyperlipidemia--: Is There More Than Lipid Lowering?. ANGIOLOGY 56: 585-592 [Abstract]  
• Youssef, F., Gupta, P., Mikhailidis, D. P., Hamilton, G. (2005). Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey. ANGIOLOGY 56: 279-287 [Abstract]  
• Daskalopoulou, S. S., Athyros, V. G., Hamilton, G., Mikhailidis, D. P. (2005). Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease. J CARDIOVASC PHARMACOL THER 10: 145-147  
• Campese, V. M., Nadim, M. K., Epstein, M. (2005). Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?. J. Am. Soc. Nephrol. 16: S11-S17 [Abstract] [Full Text]  
• Afzali, B., Haydar, A. A., Vinen, K., Goldsmith, D. J.A. (2004). From Finland to Fatland: Beneficial Effects of Statins for Patients with Chronic Kidney Disease. J. Am. Soc. Nephrol. 15: 2161-2168 [Abstract] [Full Text]  
• Afzali, B, Goldsmith, D J A (2004). Beneficial effects of statins on the kidney. J. Clin. Pathol. 57: 673-674 [Full Text]